The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | The international Prognostic Index for patients with CLL (CLL-IPI)
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses a meta-analysis of 26 prognostic factors, including clinical, biological and genetic markers, in patients with chronic lymphocytic leukemia (CLL), for the development of an internationally applicable prognostic index, known as CLL-IPI.
